8-K: Myriad Genetics Reports Strong Q4 and Full-Year 2023 Results, Raises 2024 Guidance

Myriad Genetics announced an 11% year-over-year revenue increase for both the fourth quarter and full-year 2023, alongside a raised revenue guidance for 2024.

Summary

• Myriad Genetics reported a strong financial performance for the fourth quarter and full year of 2023.
• The company's revenue reached $197 million in the fourth quarter and $753 million for the full year, both representing an 11% increase year-over-year.
• Full-year testing volume grew by 35%, or 18% excluding SneakPeek tests.
• The company achieved a GAAP EPS of $(0.36) and an adjusted EPS of $0.04 in the fourth quarter.
• Myriad Genetics raised $118 million through an equity offering in November 2023.
• In February 2024, Myriad acquired assets from Intermountain Precision Genomics, including the Precise Tumor and Precise Liquid tests.
• The company has raised its 2024 revenue guidance to $820 $840 million and introduced an adjusted EPS guidance of $0.00 $0.05.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased testing volumes, and raised 2024 guidance. The company's strategic acquisitions and new product launches further contribute to the positive outlook. However, the GAAP losses and some margin compression temper the overall sentiment slightly.

Positives

• Myriad Genetics experienced double-digit revenue growth in 2023.
• The company achieved positive adjusted EPS in the fourth quarter of 2023.
• Myriad Genetics is projecting to be profitable on an adjusted earnings per share basis for the full year 2024.
• The company has financial flexibility to invest in research and development and technology innovations.
• Myriad Genetics plans to launch new products in the second half of 2024 or early 2025.
• The company's oncology business saw a 7% and 9% year-over-year growth in hereditary cancer testing volumes and revenue, respectively, in the fourth quarter of 2023.
• Prolaris revenue grew 14% year-over-year in the fourth quarter of 2023.
• The women's health business saw a 10% year-over-year growth in hereditary cancer testing volumes in the fourth quarter of 2023.
• Pharmacogenomics testing volumes grew 21% year-over-year in the fourth quarter of 2023.
• Myriad Genetics added over 4,000 clinicians who ordered GeneSight for the first time in the fourth quarter of 2023.

Negatives

• GAAP operating loss was $31.4 million in the fourth quarter of 2023.
• GAAP cash flow from operations was $(55) million in the fourth quarter of 2023.
• GAAP gross margins decreased by 100 basis points year-over-year in the fourth quarter of 2023.
• Adjusted gross margins decreased by 110 basis points year-over-year in the fourth quarter of 2023.
• Capital expenditures and capitalization of internal use software costs were $14 million in the fourth quarter 2023.

Risks

• Sales and profit margins of existing tests may decline.
• The company may not be able to operate its business on a profitable basis.
• The company may not achieve revenue growth targets or generate sufficient revenue from new tests.
• Changes in governmental or private insurer coverage and reimbursement levels could impact revenue.
• Increased competition and the development of new competing tests pose a risk.
• The company may be unable to develop or achieve commercial success for additional tests in a timely manner.
• There are risks related to delays or problems with operating laboratory testing facilities.
• Public concern over genetic testing could negatively impact the company.
• The company may not be able to secure additional financing if needed.
• The company may not be able to protect its proprietary technologies.
• There are risks related to security breaches and cyberattacks.
• The company may not be able to keep pace with rapid technology changes in its industry.
• The company may be unable to comply with financial or operating covenants under credit agreements.
• There are risks related to current and future investigations, claims or lawsuits.

Future Outlook

Myriad Genetics has raised its 2024 revenue guidance to $820 $840 million, representing an annual growth of 9% 11% over 2023, and introduced 2024 adjusted EPS guidance of $0.00 $0.05. The company plans to launch new products in the second half of 2024 or early 2025.

Management Comments

• Myriad Genetics took another important step forward in 2023 as we generated double digit revenue growth over the prior year and achieved positive adjusted EPS in the fourth quarter.
• This achievement is the result of our teams hard work and focus on the needs of our patients and the healthcare providers who serve them.
• We believe 2024 will be an exciting year as we plan to continue to accelerate our market share gains and improve reimbursement for our products and services.
• We are also pleased to see the progress advancing our Labs of the Future strategy and technology investments, including EMR integrations, designed to enhance our ability to serve more patients seamlessly and efficiently.
• At a time, when unfortunately many other molecular diagnostic laboratories are struggling, Myriad Genetics is growing, projecting to be profitable on an adjusted earnings per share basis for full year 2024, and has the financial flexibility to continue to invest in R&D and technology innovations to achieve our Mission and Vision to reach more patients with life-saving precision medicine.

Industry Context

The announcement highlights Myriad Genetics' growth and profitability in a challenging market for molecular diagnostic laboratories, suggesting a strong competitive position and effective strategy execution. The acquisition of assets from IPG further strengthens their position in precision oncology.

Comparison to Industry Standards

• Myriad Genetics' 11% revenue growth for both Q4 and full-year 2023 is a strong performance compared to some other molecular diagnostic companies that have struggled in the same period.
• The 35% increase in full-year testing volume, or 18% excluding SneakPeek, indicates a significant market share gain, especially in the prenatal and pharmacogenomics sectors.
• The adjusted EPS of $0.04 in Q4 and the projection of profitability for 2024 are positive signs, contrasting with companies that have reported losses or reduced guidance.
• The acquisition of IPG assets, including the Precise Tumor and Precise Liquid tests, positions Myriad to compete more effectively with companies like Foundation Medicine and Guardant Health in the liquid biopsy and tumor profiling space.
• The launch of the Myriad Collaborative Research Registry (MCRR) with data from over one million patients is a significant differentiator, potentially giving them an edge over competitors in research and development.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and raised guidance.
• Employees may be encouraged by the company's growth and positive outlook.
• Customers (healthcare providers and patients) will benefit from the company's expanded product offerings and improved services.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• Myriad Genetics plans to continue to accelerate its market share gains and improve reimbursement for its products and services.
• The company will continue to invest in research and development and technology innovations.
• Myriad Genetics plans to introduce a number of new products in the second half of 2024 or early 2025, including Foresight Universal Plus, FirstGene, Precise Tumor (relaunch), Precise Liquid, and Precise MRD for research use by our pharma partners.

Key Dates

Keywords

Genetic Testing, Precision Medicine, Oncology, Womens Health, Pharmacogenomics, Hereditary Cancer, Tumor Profiling, Prenatal Testing, GeneSight, Financial Results